Now keep playing games and except for a few newbies nobody will fall for those games.
13760 posts | Last Activity: 56 seconds ago
Member since: Dec 5, 2003
One ID for nearly 12 years. That is called integrity and not like your create dozen new IDs every day to spout lies.
"pumping and bashing"
Just one instance of bashing of ADXS- show me. One MB ID and none (except when I used rvga129 when yahoo messed up a few months back). That rests my case and if it does not, I do not care- my agenda is clear cut, I do not trade a golden stock, I hold and will add more. I post my share buys each time. I have a good job and make decent money, stocks are for the nest egg. No hurry, I do not use margin, I do not invest in stocks which I bash. Clean as it gets - I am proud about it.
3 posts | Last Activity: 53 seconds ago
Member since: Jun 30, 2015
Elon Musk is working on it. I will ask him to speed up.
Stop conversing with mentally unstable my friend, the shrink can help them, it they seek help. But with paranoia like that- its karma, crooks and paranoia a bad ombination, my friend, but when they go together, paranoia takes care of crooks wrecking havoc on others.
Me and golf are very far apart. Never played golf. Grew up in a place which did not have a single golf ground- in a major metropolis. Only sports I played were cricket, badminton and ping pong.
Because it is an expensive proposition. Outfits like to make expensive things and expect profits to be huge. But Medicare has started enrolling Oncologists in care programs to cut down expenses. In fact they are going to have them plans to help cut the cost of cancer care. If you take this new paradigm in cancer care- ADXS will be the one you need to hold on to compared to the CART companies.
It is a no brainer. But that buy of 15,000 shares was a great one. I happy for you my friend.
n addition to JCAR015, Juno is developing a number of other cellular therapies. At the 2015 AACR Annual Meeting, findings were presented for JCAR017 in pediatric patients with relapsed/refractory ALL.2 In this 22-patient trial, the CD19-targeted CAR T-cell therapy JCAR017 demonstrated a 91% CR rate.
Severe neurotoxicity and/or severe CRS were observed in 36% of patients. At the time of the analysis, 4 patients had relapsed—only one of which had CD19-positive disease.
Celgene is the ideal partner for Juno to help us realize the full potential of our science and clinical research while maintaining the independence we, our employees, partners, and investors believe is so critical for true innovation, stated Hans Bishop, CEO of Juno, said in a statement. This unique collaboration is designed to catalyze and create tremendous ongoing scientific and product development synergy by leveraging each company's strengths and assets as per Mr. Bishop.
Celgene has a number of already approved therapies for patients with hematologic malignancies and other types of cancer, including pomalidomide, lenalidomide, azacitidine, romidepsin, and nab-paclitaxel. Additionally, the company has a broad research pipeline.
In addition to its established global presence and commercial reach, Celgene has leading small molecule and protein capabilities that complement Juno's advanced engineered T-cell capabilities, stated Bishop. He added, by doing this together, they believe they can more quickly and effectively develop potentially disruptive therapies in this new field of medicine and make them more readily available to patients worldwide
A number of companies are currently developing CAR-modified T-cell therapies. The CD19-targeted therapy CTL019 was the first such therapy to receive a breakthrough therapy designation from the FDA for the treatment of adult patients with ALL. CTL019 is manufactured through collaboration between the University of Pennsylvania and Novartis.
The initial focus of the collaboration will be on the development and commercialization of chimeric antigen receptor (CAR) T-cell therapies and T-cell receptor (TCR) technologies for patients with cancer and autoimmune disease, according to the statement. Celgene will have the option to commercialize these CAR and TCR therapies from Juno, including their lead agent, JCAR015, which is a CD19-targeted CAR-modified T-cell therapy.
JCAR015 was granted an FDA breakthrough therapy designation for patients with relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in November 2014. In updated findings presented at the 2015 ASCO Annual Meeting,1 JCAR015 demonstrated a complete remission (CR) rate of 87% in 38 patients with ALL. Of those who achieved a CR, 81% were MRD-negative. The median overall survival (OS) was 8.5 months, with a 6-month OS rate of 59%.
Severe cytokine release syndrome (CRS) has been the primary adverse event (AE) of concern with CAR T-cell therapies. Early in the development of these therapies, this AE caused a number of trials to be halted for safety concerns. The protocols were emended to include early detection of CRS through serum C-reactive protein testing and treatment with corticosteroids or interleukin-6 receptor blockade.
In the updated ASCO findings, severe CRS was seen in 23% of patients. The severity of this adverse event correlated with the overall disease burden and was found to be reversible with intervention. Outside of CRS, 28% of patients treated with JCAR015 experienced grade 3/4 neurotoxicity.
JCAR015 is being investigated in two phase I clinical trials. One trial is examining the agent in precursor B cell ALL, the setting in which the agent gained its orphan drug designation (NCT01840566). In the other trial, patients with relapsed/refractory aggressive B cell non-Hodgkin lymphoma (NHL) are being treated with high dose therapy and autologous stem cell transplantation followed by infusion of JCAR015 (NCT01044069).
Can we please start a list of multiple IDs of Wiz and post them daily with updates and ignore him and his multi aliases. But thanks for helping me out.
Let me clarify: If you are a good trader, your IQ should be good enough to recognize that rvga128, chinaman and J and E can not he the same. I stand out: Because my native language unlike others is not English. Hope that clarifies.
In addition those who boast about being smart traders are not smart traders. They just lubed and massaged some information from Hedgies and spout being right one time, when they were wrong on several other occasions.
Rvga128 is not a wizer. Rvga128 was invested in CVM, and was led to ADXS. I have been a holder of ADXS for several years. All MDs do not know the intricacies of Immunology and its uses for various diseases. J &E is very knowledgeable and like picdoc really good at putting things for every one to understand. Because of my background I can muster it much better then others. Wizer and this gang are here to discredit him and rob shares from LTSH. From your postings earlier I gather that you are one honest LTSH and I do not want to be fooled by the dishonest Wizer Gang.
I have added over 6000 warrants since the secondary @$19. Each downturn I have added more.
Afteer Pearson attack so many held on and some like me added a lot to decrease my $16 dollar share to under $9 because of you J&E. Prior to that I was negative 80% and at present inspite of adding more (recently with each downturn) I am still over 75% positive.